View Older Stories View More Recent Stories

Dec 9, 2021 08:34AM Zymeworks (ZYME) Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Dec 9, 2021 08:30AM Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
Dec 9, 2021 05:59AM Zymeworks' (ZYME) New Data Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
Dec 8, 2021 06:00PM Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
Dec 1, 2021 08:33AM Zymeworks (ZYME) Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric and EFECT Therapeutic Platforms
Dec 1, 2021 08:30AM Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
Nov 19, 2021 09:21AM Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
Nov 9, 2021 04:09PM Zymeworks (ZYME) Appoints Neil Josephson as Chief Medical Officer
Nov 9, 2021 04:05PM Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
Nov 9, 2021 08:30AM Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Nov 8, 2021 04:15PM Zymeworks to Present at Upcoming Investor Conferences
Nov 3, 2021 04:15PM Zymeworks Reports 2021 Third Quarter Financial Results
Oct 26, 2021 05:44AM Zymeworks (ZYME) to Webcast HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Oct 26, 2021 05:30AM Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
Oct 5, 2021 08:30AM Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumo
Sep 16, 2021 05:49AM Zymeworks (ZYME) New Data From Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Sep 16, 2021 05:30AM Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (E
Sep 12, 2021 06:49PM Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
Aug 4, 2021 04:15PM Zymeworks Reports 2021 Second Quarter Financial Results
Aug 3, 2021 08:32AM Zymeworks (ZYME) Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric and EFECT Therapeutic Platforms
Aug 3, 2021 08:30AM Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
Jul 28, 2021 08:30AM Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
Jul 8, 2021 08:30AM Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
May 26, 2021 08:30AM Zymeworks to Present at Jefferies Virtual Healthcare Conference
May 5, 2021 04:15PM Zymeworks Reports 2021 First Quarter Financial Results
Apr 19, 2021 08:38AM Zymeworks (ZYME) Announces Succession Plan for Chief Medical Officer
Apr 19, 2021 08:30AM Zymeworks Announces Succession Plan for Chief Medical Officer
Apr 13, 2021 08:30AM Zymeworks to Present at Bloom Burton Healthcare Conference
Apr 10, 2021 08:30AM Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
Mar 10, 2021 05:27PM Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Feb 24, 2021 04:15PM Zymeworks Reports 2020 Year-End Financial Results
Feb 10, 2021 04:15PM Zymeworks to Participate in Upcoming Investor Conferences and Events
Feb 9, 2021 04:30PM Zymeworks Expands Commercial Team and Creates New R&D Role
Jan 27, 2021 05:15PM Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
Jan 15, 2021 08:33AM Zymeworks (ZYME) Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO
Jan 15, 2021 08:30AM Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium
Jan 11, 2021 08:00AM Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
Jan 7, 2021 08:30AM Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two Webcasts in January to Provide Updates on its Lead Clinical Programs Zanidatamab and ZW49
Dec 10, 2020 08:30AM Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Dec 2, 2020 08:07AM Exelixis (EXEL) In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
Dec 2, 2020 08:00AM Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
View More Recent Stories View Older Stories